Coppell, TX, United States of America

D Gomika Udugamasooriya

USPTO Granted Patents = 2 

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2012-2016

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of D Gomika Udugamasooriya

Introduction

D Gomika Udugamasooriya is an accomplished inventor based in Coppell, TX (US). He has made significant contributions to the field of biochemistry, particularly in the development of high-affinity VEGF-receptor antagonists. His work has led to advancements in understanding and manipulating receptor interactions, which are crucial for various therapeutic applications.

Latest Patents

Udugamasooriya holds two patents, both focused on high-affinity VEGF-receptor antagonists. His latest patents describe a cell-based screening method that identifies specific receptor-binding compounds from a combinatorial library of peptoids, which are N-alkylglycine oligomers displayed on beads. This innovative strategy was utilized to isolate Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)-binding peptoids. These peptoids were optimized to create lead compounds with a high affinity for VEGFR2. Notably, one of these peptoids has been demonstrated to act as an antagonist of the VEGF-VEGFR2 interaction and receptor function.

Career Highlights

Udugamasooriya is affiliated with the University of Texas System, where he continues to engage in groundbreaking research. His work has not only contributed to the scientific community but has also paved the way for potential therapeutic advancements in treating diseases related to vascular growth and function.

Collaborations

He has collaborated with notable researchers such as Thomas Kodadek and Rolf A Brekken. These collaborations have enhanced the scope and impact of his research, leading to innovative solutions in the field.

Conclusion

D Gomika Udugamasooriya's contributions to the field of biochemistry through his patents and research at the University of Texas System highlight his role as a significant inventor. His work on VEGF-receptor antagonists showcases the potential for innovative therapies in addressing critical health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…